BR112020023422A2 - método para tratar fibrose pulmonar idiopática (ipf) em um indivíduo mamífero, método para inibir a proliferação ou diferenciação de miofibroblastos de pulmão em fibroblastos (fl) de pulmão fibrótico ou para redução da proliferação de fibroblastos fl, composição farmacêutica, uso da composição farmacêutica e uso de uma composição farmacêutica - Google Patents

método para tratar fibrose pulmonar idiopática (ipf) em um indivíduo mamífero, método para inibir a proliferação ou diferenciação de miofibroblastos de pulmão em fibroblastos (fl) de pulmão fibrótico ou para redução da proliferação de fibroblastos fl, composição farmacêutica, uso da composição farmacêutica e uso de uma composição farmacêutica Download PDF

Info

Publication number
BR112020023422A2
BR112020023422A2 BR112020023422-2A BR112020023422A BR112020023422A2 BR 112020023422 A2 BR112020023422 A2 BR 112020023422A2 BR 112020023422 A BR112020023422 A BR 112020023422A BR 112020023422 A2 BR112020023422 A2 BR 112020023422A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
ing
fibroblasts
pharmaceutical composition
proliferation
Prior art date
Application number
BR112020023422-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Torry A. Tucker
Steven Idell
Original Assignee
Actuate Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics, Inc. filed Critical Actuate Therapeutics, Inc.
Publication of BR112020023422A2 publication Critical patent/BR112020023422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112020023422-2A 2018-05-17 2019-05-16 método para tratar fibrose pulmonar idiopática (ipf) em um indivíduo mamífero, método para inibir a proliferação ou diferenciação de miofibroblastos de pulmão em fibroblastos (fl) de pulmão fibrótico ou para redução da proliferação de fibroblastos fl, composição farmacêutica, uso da composição farmacêutica e uso de uma composição farmacêutica BR112020023422A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672864P 2018-05-17 2018-05-17
US62/672,864 2018-05-17
PCT/US2019/032639 WO2019222483A1 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Publications (1)

Publication Number Publication Date
BR112020023422A2 true BR112020023422A2 (pt) 2021-02-17

Family

ID=68541026

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020023422-2A BR112020023422A2 (pt) 2018-05-17 2019-05-16 método para tratar fibrose pulmonar idiopática (ipf) em um indivíduo mamífero, método para inibir a proliferação ou diferenciação de miofibroblastos de pulmão em fibroblastos (fl) de pulmão fibrótico ou para redução da proliferação de fibroblastos fl, composição farmacêutica, uso da composição farmacêutica e uso de uma composição farmacêutica

Country Status (11)

Country Link
US (1) US12083098B2 (https=)
EP (1) EP3793545A4 (https=)
JP (2) JP7471660B2 (https=)
KR (1) KR20210038429A (https=)
CN (1) CN112437663A (https=)
AU (1) AU2019271285B2 (https=)
BR (1) BR112020023422A2 (https=)
CA (1) CA3100381A1 (https=)
IL (1) IL278761B2 (https=)
MX (1) MX2020012331A (https=)
WO (1) WO2019222483A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020415440A1 (en) * 2019-12-26 2022-08-04 Actuate Therapeutics, Inc. Compounds for the treatment of myelofibrosis
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib
CN117981712B (zh) * 2023-07-24 2025-02-28 南京鼓楼医院 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622987C (en) 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
KR101862291B1 (ko) * 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014165851A1 (en) 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Also Published As

Publication number Publication date
CN112437663A (zh) 2021-03-02
JP7471660B2 (ja) 2024-04-22
US12083098B2 (en) 2024-09-10
JP2024069221A (ja) 2024-05-21
US20210212988A1 (en) 2021-07-15
EP3793545A4 (en) 2022-04-06
KR20210038429A (ko) 2021-04-07
IL278761A (en) 2021-01-31
WO2019222483A1 (en) 2019-11-21
MX2020012331A (es) 2021-03-09
AU2019271285B2 (en) 2024-10-03
CA3100381A1 (en) 2019-11-21
EP3793545A1 (en) 2021-03-24
AU2019271285A1 (en) 2020-12-03
IL278761B1 (en) 2024-11-01
IL278761B2 (en) 2025-03-01
JP2021523951A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
Endo Calcium release from the sarcoplasmic reticulum
Novella Romanelli et al. HCN channels modulators: the need for selectivity
JP2024069221A (ja) グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
BR112017016392B1 (pt) Agente terapêutico para câncer do ducto biliar
JP2016520130A (ja) 心臓疾患における新規治療戦略としてのｂｅｔ阻害
PT804191E (pt) Uso de inibidores do receptor do factor de crescimento derivado das plaquetas no fabrico de um medicamento para o tratamento de cancros
US11529324B2 (en) Use of Kv11.1 channel inhibitors for treatment of pulmonary hypertension
US7696160B2 (en) Compositions useful for and methods of modulating angiogenesis
JP2010046062A (ja) 脳損傷の予後改善薬のスクリーニング方法
Li et al. Acidic tumor microenvironment-sensitive liposomes enhance colorectal cancer therapy by acting on both tumor cells and cancer-associated fibroblasts
JP2022519777A (ja) 処置誘導性の胃腸傷害を防止又は処置する方法
AU2019338236B2 (en) A GABAA receptor ligand
BRPI0718630A2 (pt) Inibidores de acat e sua utilização na prevenção ou tratamento de fibrose.
JP4993606B2 (ja) Ｒａｍｐ２を標的とする血管構造の安定化剤及び血管新生剤
JP6688503B2 (ja) 医薬用組成物
JPWO2006134692A6 (ja) Ｒａｍｐ２を標的とする血管構造の安定化剤及び血管新生剤
EP2582384B1 (en) Compositions and methods for treating cancer
US11484536B2 (en) Method of treating metastatic cancer in a subject with a protein inhibitor
US20240000977A1 (en) Methods and kits for diagnosing and treating cancers
WO2025077707A1 (zh) 用于自身免疫疾病治疗的s1pr4调节剂化合物及其应用
CN119330974A (zh) Quinadolin B及其结构类似物在制备用于预防和治疗黑色素瘤药物方面的用途
WO2010003287A1 (zh) 2-(α-羟基戊基)苯甲酸钾预防和\或治疗老年痴呆的用途
BR122024006410A2 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson
BR112018074439B1 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.